US patent covers automated methods for detecting the translocation of a cellular component between a first and second cellular compartment on and/or within individual cells
Cellomics reports that the US Patent Office has issued US patent number 6,620,591 covering the automated methods for detecting the translocation of a cellular component of interest between a first cellular compartment and a second cellular compartment on and/or within individual cells.
This issuance adds to Cellomics's portfolio of global patents which include both broad claims to high content screening (HCS) technology as well as specific classes of HCS assays such as cytoplasm-nuclear translocation, characterisation of cellular toxicity, and receptor internalisation.
Cellomics has 28 additional patents that have been allowed or are currently pending in the field of HCS.
In addition, Cellomics has separate patent estates for the CellChip system, which it calls 'the miniaturised cell analysis platform of the future', and a variety of fluorescence-based biosensors that are live reporters of the function, activity, or environment of intracellular targets.
"The patent position of Cellomics continues to grow in the emerging market of high content screening", stated Jeffrey Haskins, VP of assay development.
"Cellomics invested heavily in the development and patenting of the technologies we created and our patent portfolio places us in the leadership position". "Cellomics has initiated a licensing programme to broaden the availability of HCS to other biotools and biotechnology companies", stated Daniel Calvo, president and CEO of Cellomics.
"Our desire is to help to broaden the growth of the market through our licensing programme".
